Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Zai Lab Acquires Global Rights to Two GSK Anti-Inflammatory Assets

publication date: Oct 19, 2016
Zai Lab of Shanghai in-licensed global rights to two anti-inflammatory candidates from GlaxoSmithKline. Zai did not disclose many details about the assets, which target multiple anti-inflammatory indications, except to say that one is in a Phase II trial and the other in pre-clinical development. Zai's rights to the drugs include global commercialization. Zai already has two other molecules for anti-inflammation in clinical development, one targets asthma/COPD, the other targets graft-versus-host/irritable bowel syndrome. More details....

Stock Symbol: (NYSE: GSK)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital